Stock 1099 SINOPHARM GROUP CO. LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Sinopharm Group Co. Ltd.

Equities

1099

CNE100000FN7

Market Closed - Hong Kong S.E.
Other stock markets
 04:09:09 2024-04-25 am EDT 		5-day change 1st Jan Change
21.75 HKD +0.69% Intraday chart for Sinopharm Group Co. Ltd. +9.63% +6.36%
Apr. 16 Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets MT
Apr. 10 Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials MT

Evolution of the average Target Price on Sinopharm Group Co. Ltd.

Price target over the last 5 years

History of analyst recommendation changes

b2f40e78d8a3d7abfd17d6a7be20.W6MTFCe-6DAvmQfhJhDah9WPEpliOPjhC3eTgRwJX9w.b8xJV0bw2nxnwUWLRFu0w622ZdxQdJqsWEGjw25zGJ0D7lhdVoqdCFWoPw~46dfa950b98eb0d5e9aab4c3cc1e2cfb

Analyst Recommendations on Sinopharm Group Co. Ltd.

Nomura Adjusts Sinopharm Group’s Price Target to HK$32.39 Form HK$33.31, Keeps at Buy MT
Interest Rates, Earnings, FX Roil Asian Stock Markets MT
Nomura Adjusts Sinopharm Group's Price Target to HK$33.31 From HK$36.28, Keeps at Buy MT
Nomura Adjusts Sinopharm's Price Target to HK$36.28 From HK$36.88, Keeps at Buy MT
UBS Adjusts Sinopharm Group's Price Target to HK$26 From HK$28, Keeps at Buy MT
UBS Adjusts Sinopharm's Price Target to HK$28 From HK$30, Keeps at Buy MT
WHO sees more evidence that Omicron causes milder symptoms RE
WHO sees more evidence that Omicron causes milder symptoms RE
Kenya to start giving COVID-19 booster shots RE
Sinovac Biotech : China considers mixing COVID-19 vaccines to boost protection rate RE
Sinovac Biotech : China considering mixing COVID-19 vaccines due to low efficacy rates RE
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
19.98 CNY
Average target price
25.06 CNY
Spread / Average Target
+25.42%
High Price Target
29.79 CNY
Spread / Highest target
+49.06%
Low Price Target
20.2 CNY
Spread / Lowest Target
+1.07%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Sinopharm Group Co. Ltd.

Nomura
UBS

Ratings for Sinopharm Group Co. Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. 1099 Stock
  4. Consensus Sinopharm Group Co. Ltd.